In the first-line treatment of advanced HER2-positive (HER2+) breast cancer, the standard regimen of taxane-trastuzumab-pertuzumab (THP) provides a median progression-free survival (PFS) of approximately 18–21 months and a median overall survival (OS) of around 57–65 months1,2. This evidence concerns the gene ERBB2 and breast carcinoma.